<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381742</url>
  </required_header>
  <id_info>
    <org_study_id>ACS-2</org_study_id>
    <nct_id>NCT03381742</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Low-dose Ticagrelor</brief_title>
  <official_title>Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Jia Mu Si City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guideline recommendations on the use of dual antiplatelet therapy have been formulated that
      ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus
      aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could
      significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular
      events. The previous studies have reported that half-dose ticagrelor had the similar
      inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was
      significantly stronger than that in the clopidogrel group. One-quarter standard-dose
      ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in
      Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm
      the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary
      heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a
      cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one
      of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine
      diphosphate (ADP) receptor.

      Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used
      clinically for the prevention of atherothrombotic events in patients with acute coronary
      syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been
      formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg
      daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day
      orally could significantly reduce the occurrence of clopidogrel resistance and adverse
      cardiovascular events. The previous studies have reported that half-dose ticagrelor had the
      similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was
      significantly stronger than that in the clopidogrel group. One-quarter standard-dose
      ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in
      Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm
      the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary
      heart disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADP-induced Inhibition of Platelet Aggregation</measure>
    <time_frame>up to 5 days</time_frame>
    <description>The venous blood samples for platelet function test were drawn after an overnight fast, at 12 hours post-last study-drug dose for subjects receiving twice-daily administrations, and at 24 hours post-last study-drug dose for subjects treated with once-daily regimens. The blood was collected in an evacuated vacuum tube containing 3.2% trisodium citrate and lithium heparin. Then the samples were processed within two hours of blood draw according to standard operating procedure. The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced inhibition of platelet aggregation (IPA, range 0% - 100%), with higher values indicating greater platelet inhibition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Bleeding (Major or Minor Bleeding)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Major bleeding was defined as type ≥ 3 and minor bleeding as types 1 and 2, in accordance to the Bleeding Academic Research Consortium classification. (Mehran R et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADP-induced Platelet-fibrin Clot Strength (MA)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced platelet-fibrin clot strength (MA). A MA&gt;47mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested MA&lt;31 mm as a predictive value for post-PCI bleeding events (J Am Coll Cardiol. 2013;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With High On-Treatment Platelet Reactivity (HTPR)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>HTPR was defined as IPA ≤ 30% and MA ≥ 47 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Event (Cardiovascular Death, New-onset Myocardial Infarction, or Stroke)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Cardiovascular death was defined as sudden cardiac death, fatal myocardial infarction, death due to heart failure, or death due to other cardiovascular causes. Stroke was defined as the focal loss of neurologic function caused by an ischemic or a hemorrhagic event with residual symptoms lasting at least 24 hours or eventually leading to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New-onset Dyspnea</measure>
    <time_frame>up to 5 days</time_frame>
    <description>New-onset dyspnea in patients without previous history of dyspnea</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3043</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>ticagrelor 45mg bidpo.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor 90mg qdpo.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor 90mg bidpo.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel 75mg qdpo.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
    <arm_group_label>ticagrelor 45mg bidpo.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
    <arm_group_label>ticagrelor 90mg qdpo.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
    <arm_group_label>ticagrelor 90mg bidpo.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
    <arm_group_label>clopidogrel 75mg qdpo.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with coronary artery disease

        Exclusion Criteria:

          -  younger than 18 years of age;

          -  anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;

          -  previous or current treatment with any other potentially confounding drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Department, the First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thromboela-Stogram</name>
      <address>
        <city>Beijing</city>
        <zip>100001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <results_first_submitted>July 4, 2019</results_first_submitted>
  <results_first_submitted_qc>August 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03381742/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3,737 CAD patients who received either clopidogrel or ticagrelor therapy and underwent TEG test from 11 medical centers. Among these patients, 1,725 subjects were treated with clopidogrel and 2,012 subjects were treated with different ticagrelor regimens.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor 45mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor 90mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="P3">
          <title>Clopidogrel 75mg Qdpo.</title>
          <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="P4">
          <title>Ticagrelor 90mg Qdpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="525"/>
                <participants group_id="P2" count="501"/>
                <participants group_id="P3" count="1511"/>
                <participants group_id="P4" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="525"/>
                <participants group_id="P2" count="501"/>
                <participants group_id="P3" count="1511"/>
                <participants group_id="P4" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clopidogrel 75mg Qdpo.</title>
          <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor 90mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="B3">
          <title>Ticagrelor 45mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="B4">
          <title>Ticagrelor 90mg Qdpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1511"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="525"/>
            <count group_id="B4" value="506"/>
            <count group_id="B5" value="3043"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="55" upper_limit="69"/>
                    <measurement group_id="B2" value="61" lower_limit="52" upper_limit="67"/>
                    <measurement group_id="B3" value="62" lower_limit="55" upper_limit="69"/>
                    <measurement group_id="B4" value="62" lower_limit="55" upper_limit="68"/>
                    <measurement group_id="B5" value="62" lower_limit="55" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="532"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="237"/>
                    <measurement group_id="B5" value="1129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="979"/>
                    <measurement group_id="B2" value="342"/>
                    <measurement group_id="B3" value="324"/>
                    <measurement group_id="B4" value="269"/>
                    <measurement group_id="B5" value="1914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1511"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="525"/>
                    <measurement group_id="B4" value="506"/>
                    <measurement group_id="B5" value="3043"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1511"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="525"/>
                    <measurement group_id="B4" value="506"/>
                    <measurement group_id="B5" value="3043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="63" upper_limit="78"/>
                    <measurement group_id="B2" value="70" lower_limit="62" upper_limit="78"/>
                    <measurement group_id="B3" value="70" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="B4" value="70" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="B5" value="70" lower_limit="62" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="736"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="226"/>
                    <measurement group_id="B4" value="202"/>
                    <measurement group_id="B5" value="1398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="879"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="332"/>
                    <measurement group_id="B4" value="287"/>
                    <measurement group_id="B5" value="1741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diabetes mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>chronic kidney disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>percutaneous coronary intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1056"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="1802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>coronary artery bypass grafting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total cholesterol</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" lower_limit="3.4" upper_limit="5.1"/>
                    <measurement group_id="B2" value="3.9" lower_limit="2.6" upper_limit="5"/>
                    <measurement group_id="B3" value="4.3" lower_limit="3.4" upper_limit="5.3"/>
                    <measurement group_id="B4" value="4.7" lower_limit="3.8" upper_limit="5.7"/>
                    <measurement group_id="B5" value="4.24" lower_limit="3.39" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>triglyceride</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" lower_limit="1.2" upper_limit="2.4"/>
                    <measurement group_id="B2" value="1.9" lower_limit="1.3" upper_limit="3.6"/>
                    <measurement group_id="B3" value="1.7" lower_limit="1.2" upper_limit="2.7"/>
                    <measurement group_id="B4" value="1.6" lower_limit="1.1" upper_limit="2.4"/>
                    <measurement group_id="B5" value="1.67" lower_limit="1.17" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>high density lipoprotein</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="B3" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="B4" value="1.2" lower_limit="1" upper_limit="1.4"/>
                    <measurement group_id="B5" value="1.1" lower_limit="0.93" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>low density lipoprotein</title>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" lower_limit="2.1" upper_limit="3.2"/>
                    <measurement group_id="B2" value="2.8" lower_limit="2.1" upper_limit="3.3"/>
                    <measurement group_id="B3" value="2.7" lower_limit="2.2" upper_limit="3.3"/>
                    <measurement group_id="B4" value="2.9" lower_limit="2.4" upper_limit="3.6"/>
                    <measurement group_id="B5" value="2.68" lower_limit="2.17" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>creatinine</title>
          <units>μmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="61.4" upper_limit="82.9"/>
                    <measurement group_id="B2" value="69.7" lower_limit="59.2" upper_limit="81"/>
                    <measurement group_id="B3" value="68.7" lower_limit="59.1" upper_limit="80.7"/>
                    <measurement group_id="B4" value="67.7" lower_limit="57.6" upper_limit="79.6"/>
                    <measurement group_id="B5" value="69.9" lower_limit="59.5" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>uric acid</title>
          <units>μmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330" lower_limit="276" upper_limit="390"/>
                    <measurement group_id="B2" value="338" lower_limit="280" upper_limit="408"/>
                    <measurement group_id="B3" value="323" lower_limit="268" upper_limit="385"/>
                    <measurement group_id="B4" value="320" lower_limit="266" upper_limit="387"/>
                    <measurement group_id="B5" value="328.4" lower_limit="271.5" upper_limit="391.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>aspirin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1429"/>
                    <measurement group_id="B2" value="446"/>
                    <measurement group_id="B3" value="475"/>
                    <measurement group_id="B4" value="443"/>
                    <measurement group_id="B5" value="2793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>acute myocardial infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ADP-induced Inhibition of Platelet Aggregation</title>
        <description>The venous blood samples for platelet function test were drawn after an overnight fast, at 12 hours post-last study-drug dose for subjects receiving twice-daily administrations, and at 24 hours post-last study-drug dose for subjects treated with once-daily regimens. The blood was collected in an evacuated vacuum tube containing 3.2% trisodium citrate and lithium heparin. Then the samples were processed within two hours of blood draw according to standard operating procedure. The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced inhibition of platelet aggregation (IPA, range 0% - 100%), with higher values indicating greater platelet inhibition.</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>ADP-induced Inhibition of Platelet Aggregation</title>
          <description>The venous blood samples for platelet function test were drawn after an overnight fast, at 12 hours post-last study-drug dose for subjects receiving twice-daily administrations, and at 24 hours post-last study-drug dose for subjects treated with once-daily regimens. The blood was collected in an evacuated vacuum tube containing 3.2% trisodium citrate and lithium heparin. Then the samples were processed within two hours of blood draw according to standard operating procedure. The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced inhibition of platelet aggregation (IPA, range 0% - 100%), with higher values indicating greater platelet inhibition.</description>
          <units>percentage of inhibition of platelet agg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="31.9" upper_limit="79.1"/>
                    <measurement group_id="O2" value="80.6" lower_limit="64.1" upper_limit="94"/>
                    <measurement group_id="O3" value="73.6" lower_limit="52.6" upper_limit="93.7"/>
                    <measurement group_id="O4" value="66" lower_limit="46.9" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bleeding (Major or Minor Bleeding)</title>
        <description>Major bleeding was defined as type ≥ 3 and minor bleeding as types 1 and 2, in accordance to the Bleeding Academic Research Consortium classification. (Mehran R et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.)</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding (Major or Minor Bleeding)</title>
          <description>Major bleeding was defined as type ≥ 3 and minor bleeding as types 1 and 2, in accordance to the Bleeding Academic Research Consortium classification. (Mehran R et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Minor bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Major bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1496"/>
                    <measurement group_id="O2" value="471"/>
                    <measurement group_id="O3" value="511"/>
                    <measurement group_id="O4" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADP-induced Platelet-fibrin Clot Strength (MA)</title>
        <description>The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced platelet-fibrin clot strength (MA). A MA&gt;47mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested MA&lt;31 mm as a predictive value for post-PCI bleeding events (J Am Coll Cardiol. 2013;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101.).</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>ADP-induced Platelet-fibrin Clot Strength (MA)</title>
          <description>The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced platelet-fibrin clot strength (MA). A MA&gt;47mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested MA&lt;31 mm as a predictive value for post-PCI bleeding events (J Am Coll Cardiol. 2013;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101.).</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" lower_limit="27" upper_limit="51.6"/>
                    <measurement group_id="O2" value="28.4" lower_limit="18.5" upper_limit="38.9"/>
                    <measurement group_id="O3" value="32.3" lower_limit="19.5" upper_limit="43.9"/>
                    <measurement group_id="O4" value="34.05" lower_limit="23.6" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With High On-Treatment Platelet Reactivity (HTPR)</title>
        <description>HTPR was defined as IPA ≤ 30% and MA ≥ 47 mm.</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High On-Treatment Platelet Reactivity (HTPR)</title>
          <description>HTPR was defined as IPA ≤ 30% and MA ≥ 47 mm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HTPR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-HTPR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1194"/>
                    <measurement group_id="O2" value="488"/>
                    <measurement group_id="O3" value="502"/>
                    <measurement group_id="O4" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Event (Cardiovascular Death, New-onset Myocardial Infarction, or Stroke)</title>
        <description>Cardiovascular death was defined as sudden cardiac death, fatal myocardial infarction, death due to heart failure, or death due to other cardiovascular causes. Stroke was defined as the focal loss of neurologic function caused by an ischemic or a hemorrhagic event with residual symptoms lasting at least 24 hours or eventually leading to death.</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Event (Cardiovascular Death, New-onset Myocardial Infarction, or Stroke)</title>
          <description>Cardiovascular death was defined as sudden cardiac death, fatal myocardial infarction, death due to heart failure, or death due to other cardiovascular causes. Stroke was defined as the focal loss of neurologic function caused by an ischemic or a hemorrhagic event with residual symptoms lasting at least 24 hours or eventually leading to death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Participants with cardiovascular death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants without cardiovascular events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1511"/>
                    <measurement group_id="O2" value="501"/>
                    <measurement group_id="O3" value="525"/>
                    <measurement group_id="O4" value="506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants with new-onset myocardial infarction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants with stroke</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New-onset Dyspnea</title>
        <description>New-onset dyspnea in patients without previous history of dyspnea</description>
        <time_frame>up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75mg Qdpo.</title>
            <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 90mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 45mg Bidpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
          </group>
          <group group_id="O4">
            <title>Ticagrelor 90mg Qdpo.</title>
            <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New-onset Dyspnea</title>
          <description>New-onset dyspnea in patients without previous history of dyspnea</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1511"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="525"/>
                <count group_id="O4" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Participants with new-onset dyspnea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants without new-onset dyspne</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1477"/>
                    <measurement group_id="O2" value="472"/>
                    <measurement group_id="O3" value="493"/>
                    <measurement group_id="O4" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel 75mg Qdpo.</title>
          <description>To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
clopidogrel: clopidogrel 75 mg once daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor 90mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="E3">
          <title>Ticagrelor 45mg Bidpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
Ticagrelor: ticagrelor 45 mg twice daily for 5 consecutive days at least.</description>
        </group>
        <group group_id="E4">
          <title>Ticagrelor 90mg Qdpo.</title>
          <description>To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
ticagrelor: ticagrelor 90 mg once daily for 5 consecutive days at least.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1511"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="506"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1511"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="506"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1511"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="506"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yue Li</name_or_title>
      <organization>Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin, China</organization>
      <phone>86-451-85555673</phone>
      <email>ly99ly@vip.163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

